The National Comprehensive Cancer Network® (NCCN®) and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Recommend mCRPC Patients Be Monitored Closely for Progression1,2

  • NCCN® recommends using PSA tests, radiologic imaging (ie, CT, bone scan), and clinical exams to monitor closely for progression
  • PCWG3 has also published additional recommendations
Monitoring recommendations/
guidelines by NCCN® for metastatic disease1
Indicators of disease progression according to PCWG32
PSA measurement every 3-6 months based on clinical judgment

Increased risk for bone metastasis or death with a PSADT of <8 months
Rising PSA levels
Frequency of imaging should be based on individual risk, age, PSADT, Gleason score, and overall health, ie, bone scans* every 8-12 weeks

PSADT <8 months, perform bone imaging more frequently
New lesions
History and physical examination every 3-6 months Pain

CT=computed tomography; mCRPC=metastatic castration-resistant prostate cancer; PSA=prostate-specific antigen; PSADT=PSA doubling time.

*Bone scans are useful to monitor mCRPC to determine the clinical benefit of systematic therapy. However, new lesions comparing pre- and post-treatment bone scans may not indicate disease progression. New lesions in the setting of a falling PSA or soft tissue response and in the absence of pain progression at the site may indicate bone scan flare or an osteoblastic healing reaction.

Explore the chemical structure of JEVTANA